Journal
VACCINE
Volume 37, Issue 13, Pages 1844-1852Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2019.02.010
Keywords
Leptospira; Leptospiral Immunoglobulin-like; Subunit vaccine; DNA vaccine; Protection
Categories
Funding
- CNPq
- CAPES
- FAPERGS
Ask authors/readers for more resources
Leptospirosis is a zoonosis of worldwide distribution, caused by infection with pathogenic Leptospira species. The vaccines that are currently available are bacterins, with limited human use, that confer shortterm, serovar-specific immunity. Lig proteins are considered to be the best vaccine candidates to date. Here, we aimed to construct a recombinant Lig chimera (LC) comprised of LigAni and LigBrep fragments, and to evaluate it as subunit or DNA vaccine using different administration strategies. Vaccines were formulated with 50 mu g of recombinant LC associated with different adjuvants or with 100 mu g of pTARGET/LC. Four-week-old hamsters received two doses of vaccine with different strategies and were challenged with 5 x DL50 Leptospira interrogans serovar Copenhageni strain Fiocruz L1-130. The immune response generated by Lig chimera conferred 100% protection to hamsters treated with at least one dose of recombinant LC. Despite the high levels of antibodies that vaccinated animals produced, a sterilizing immunity was not achieved. The lack of a sterilizing immunity could indicate the importance of a mixed humoral and cellular immune response. The present study generated insights that will be useful in the future development of improved subunit vaccines against leptospirosis. (C) 2019 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available